Vaxcyte, Inc. (PCVX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92243G1085
Vaxcyte, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -923.68 m USD |
| EBIT | -886.35 m USD |
| Net income | -766.63 m USD |
| Diluted EPS – continuing operations | -5.63 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
More stocks
- Groep Brussel Lambert NV (GBLB.BR)
- Edison SpA (EDNR.MI)
- REPLIGEN CORP (RGEN)
- Harmony Gold Mining Company Ltd (HAR.JO)
- RAMBUS INC (RMBS)
- Sasol Ltd (SOL.JO)
- Qorvo, Inc. (QRVO)
- China Shipbuilding Industry Group Power Co Ltd (600482.SS)
- Antero Midstream Corp (AM)
- HECLA MINING CO/DE/ (HL)
- M&G PLC (MNG.L)
- DARLING INGREDIENTS INC. (DAR)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.